Spyre Therapeutics (SYRE) Non Operating Income (2015 - 2026)

Spyre Therapeutics (SYRE) has 12 years of Non Operating Income data on file, last reported at -$23.4 million in Q1 2026.

• Quarterly Non Operating Income fell 366.14% year-over-year to -$23.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.2 million (up 308.93% YoY) and the FY2025 annual result came in at $54.3 million, up 8972.45% from the prior year.
• Non Operating Income slipped to -$23.4 million in Q1 2026, from -$5.4 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $45.7 million in Q3 2025 to a low of -$57.8 million in Q2 2023.
• A 5-year average of -$3.8 million and a median of $312000.0 in 2022 frame the typical range for Non Operating Income.
• The widest YoY moves for Non Operating Income: up 6860.0% in 2023, down 53153.21% in 2023.
• Tracing SYRE's Non Operating Income over 5 years: stood at $378000.0 in 2022, then slumped by 4667.72% to -$17.3 million in 2023, then jumped by 128.72% to $5.0 million in 2024, then tumbled by 208.07% to -$5.4 million in 2025, then plunged by 336.06% to -$23.4 million in 2026.
• The last three Non Operating Income figures came in at -$23.4 million (Q1 2026), -$5.4 million (Q4 2025), and $45.7 million (Q3 2025), per Business Quant data.